Fate of drugs during wastewater treatment by Petrie, B et al.
Fate of drugs during wastewater treatment  
 
Bruce Petrie
1
, Ewan J. McAdam
1
, Mark D. Scrimshaw
2
, John N. Lester
1
 and Elise Cartmell
1
* 
 
1
Cranfield Water Science Institute, Cranfield University, Bedfordshire, MK43 0AL, UK. 
2
Institute for the Environment, Brunel University, Middlesex UB8 3PH, UK. 
 
*corresponding author telephone: +44 (0)1234 758366 email: e.cartmell@cranfield.ac.uk 
 
Abstract 
Recent trends for the determination of pharmaceutical drugs in wastewaters focus on the 
development of rapid multi-residue methods.  These encompass a large number of drugs (up 
to 90) of varying physicochemical composition (hydrophobicity, molecular weight etc) at ng 
l
-1
 concentrations in the aqueous phase of complex heterogeneous matrices.  These are well 
suited for drug determination in secondary effluents which contain detectable concentrations 
of pharmaceuticals.  Drugs are not routinely monitored for in particulate phases of 
wastewaters despite being essential for fate determination, particularly in secondary processes 
receiving relatively high concentrations of suspended solids.  Secondary effluents tend to 
contain multiple drugs, often above their proposed legislative targets for consent.  Thus, 
tertiary processing may be considered to enhance drug removal and provide additional 
environmental protection.  However, current analytical methods do not enable the efficacy of 
tertiary processes to be fully ascertained due to the inherently lower drug concentrations 
achieved.  Existing method optimisation is required to lower detection capabilities for tertiary 
process monitoring.  This would aid the understanding of breakdown reaction completeness 
and the criticality between parent drug and degradation product concentrations.  Numerous 
degradation products are formed by biological and chemical processes which can exhibit 
toxicity.  The complimentary use of biological assays here would improve understanding of 
the synergistic toxicological effect of multiple drugs and their degradation products at low 
concentration.  Additionally, tertiary processes receive secondary effluents comprising 
comparatively high concentrations of dissolved organics (e.g., colloids).  However, 
knowledge of drug behaviour in the charged colloidal fraction of wastewater and its impact to 
treatment is limited.  Monitoring and understanding here is needed to develop tertiary process 
diagnosis and optimisation. 
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1. Introduction  
It is well established that wastewater contains a diverse range of anthropogenic compounds 
[1] and that their quantitative analysis poses numerous problems analytically, both in terms of 
extraction efficiency [2] and interference from co-extractives [3].  Through medical use large 
numbers of drugs are now included in this group of determinants [4-7].  A clear trend in 
legislation has been a lowering of acceptable environmental concentrations (e.g., 17α-
ethinylestradiol (EE2)) and analytical method development has become an iterative process to 
achieve ever lower detection limits [8-9] as further potential environmental health issues 
emerge [10]. A growing understanding of the possible environmental impact to aquatic 
ecosystems has led to the classification of diclofenac and the steroid estrogen EE2 as priority 
hazardous chemicals [11-12].  These drugs have proposed environmental quality standards 
(EQS) of 100 ng l
-1
 and 0.035 ng l
-1
 respectively, and require monitoring to ensure compliance 
to ‘good’ water status [11-12].  The effects of EE2, which results in intersex in male fish, are 
the most studied of the drugs in the environment [13].  Concentrations of EE2 below 1 ng l
-1
 
are known to cause intersex and vitellogenin induction in male fish during laboratory studies.  
The environmental impact of other drugs and mixtures is less clear.  However, it has been 
demonstrated that a mixture of acetaminophen, carbamazepine, gemfibrozil and venlaflaxine 
(in the low µg l
-1
 range) had a significant impact to fish embryo development in the short term 
[14].  The chronic impact of drugs (i.e., ecological and evolutionary), either individually or as 
mixtures, remains unknown [15].  Without such information it is desirable to limit entry of 
these chemicals into the aquatic environment.  A total of 12 drugs of varying therapeutic class 
(ibuprofen, diclofenac, naproxen, ketoprofen, carbamazepine, bezafibrate, propranolol, 
fluoxetine, EE2, ofloxacin, erythromycin and oxytetracycline) are highlighted in this review 
to represent a variety of physicochemical compositions (e.g., molecular size, hydrophobicity) 
(Table 1).  This includes those most studied in the literature [7, 17-18] and those in national 
studies (i.e., the UK Chemical Investigations Programme (CIP)) [19].  The CIP found 
diclofenac, propranolol, fluoxetine, EE2, erythromycin and oxytetracycline above their 
indicative legislative targets for consent (10 ng l
-1
 for those not listed as priority hazardous 
substances) in over 50 % of effluents studied [19].  Consequently, a variety of drugs have 
been observed in surface waters in the ng l
-1
 range (Table 2).  This underpins the need to 
understand drug fate during wastewater treatment for process/strategy optimisation.   
 
Determining drug fate during wastewater treatment relies on the application of robust 
analytical methodologies.  These require the ability to simultaneously determine a number of 
drugs, of differing physicochemical properties, within environmental matrices comprised of 
comparatively high concentrations of complex bulk organics [23].  The high complexity of 
environmental matrices underlines the analytical challenge posed.  Drugs and their 
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Table 1. Physicochemical properties of pharmaceutical drugs present in crude wastewaters and 
secondary effluents [16] 
Drug 
MW 
/ g mol
-1
 
Water solubility  
/ mg l
-1
 
Henry’s law  
/ atm m
3
 mol
-1
 
VP  
/ mm Hg 
pKa Log Kow Log Koc 
Ibuprofen 206.30 21.0 1.52.10
-7
 1.86.10
-4
 4.91 3.79-3.97 2.35 
Diclofenac 296.15 2.4 4.73.10
-12
 2.18.10
-6
 4.15 4.02-4.51 2.61 
Naproxen 230.26 15.9 3.39.10
-10
 1.27.10
-6
 4.15 3.10-3.18 1.97 
Ketoprofen 254.28 51.0 2.12.10
-11
 6.81.10
-6
 4.45 3.00-3.12 2.08 
Carbamazepine 236.27 112 1.08.10
-10
 8.80.10
-8
 - 2.25-2.45 2.23 
Bezafibrate 361.82 7.9 2.12.10
-15
 6.12.10
-11
 - 4.25 2.31 
Propranolol 259.35 61.7 7.98.10
-13
 9.44.10
-8
 9.42 2.60-3.48 2.45 
Fluoxetine 309.33 60.3 8.90.10
-8
 2.52.10
-5
 - 4.05-4.65 4.97 
EE2 296.40 11.3 7.94.10
-12
 1.95.10
-9
 - 3.67-4.12 4.65 
Ofloxacin 361.37 2.8.10
4
 4.98.10
-20
 9.84.10
-13
 - <0 1.09 
Erythromycin 733.94 0.5 5.42.10
-29
 2.12.10
-25
 8.88 2.48-3.06 2.75 
Oxytetracycline 460.43 313 1.70.10
-25
 9.05.10
-23
 3.27 <0 1.87 
KEY: MW, molecular weight; VP, vapour pressure; pKa, acid dissociation constant; Log Kow, octanol-
water coefficient; Log Koc, organic carbon-water coefficient 
 
 
metabolites were first reported in wastewater effluents in the 1970’s [24].  Hignite et al [24] 
measured chlorophenoxyisobutyrate and salicylic acid in wastewater effluents at relatively 
high mean concentrations of 7 µg l
-1
 and 29 µg l
-1
, respectively.  Ion exchange 
chromatography was used for extraction followed by gas chromatography-mass spectrometry 
(GC-MS).  Numerous other drugs have been given significant attention recently due to the 
development of sophisticated analytical methodologies [17-18, 25].  Extraction media 
enabling simultaneous retention of acidic, basic and neutral species of varying polarities has 
aided this.  Furthermore, the coupling of liquid chromatography (LC), and particularly ultra-
performance liquid chromatography (UPLC) to MS has seen significant reductions in sample 
pre-treatment requirements and instrument analysis time [23].  Other than analytical 
difficulties, the variety of physicochemical behaviour (e.g., hydrophobicity) exhibited by 
drugs results in significant differences in their fate and removal during wastewater treatment 
[6, 26].  Tertiary treatment processes are being considered to enhance hazardous chemical 
removal to levels which comply with proposed EQS’s [27], as are the analytical methods 
capable of supporting their diagnosis and optimisation for this critical group of emerging 
chemicals.  This review addresses recent analytical trends for drug determination in 
environmental matrices used to facilitate fate studies.  Analytical requirements for further fate 
evaluation and tertiary process selection/optimisation are also discussed. 
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Table 2.  Recently reported occurrence of pharmaceutical drugs in surface waters  
Drug of 
interest 
Class Chemical structure 
Proposed 
legislative 
target / ng l
-1
 
Surface 
water
a
 / ng l
-1
 
Location 
Ibuprofen NSAID 
 
10
b
 
<0.3-56 
<6.4-542 
21-2,796 
UK 
Mainland Europe 
North America 
Diclofenac NSAID 
 
100
c
 
<0.5-261 
<12-154 
17-42 
UK 
Mainland Europe 
North America 
Naproxen NSAID 
 
- 
<0.3-55 
<3.1-109 
22 
UK 
Mainland Europe 
North America 
Ketoprofen NSAID 
 
- 
<0.5-4 
<15-517 
- 
UK 
Mainland Europe 
North America 
Carbamazepine Anti-epileptic 
 
- 
0.5-495 
<1.5-54 
1-1,238 
UK 
Mainland Europe 
North America 
Bezafibrate 
Lipid 
regulator 
 
- 
<10-66 
<2.0-26 
- 
UK 
Mainland Europe 
North America 
Propranolol Beta blocker 
 
10
b
 
<0.5-27 
<0.4-39 
53 
UK 
Mainland Europe 
North America 
Fluoxetine 
Anti-
depressant 
 
10
b
 
- 
<7.4-24 
<1.3-65 
UK 
Mainland Europe 
North America 
EE2 Contraceptive 
 
0.035
c
 
- 
- 
- 
UK 
Mainland Europe 
North America 
Ofloxacin Antibiotic 
 
10
b
 
- 
4.8-105 
- 
UK 
Mainland Europe 
North America 
Erythromycin Antibiotic 
 
10
b
 
<0.5-20 
<28-52 
2-438 
UK 
Mainland Europe 
North America 
Oxytetracycline Antibiotic 
 
10
b
 
- 
<12-37 
- 
UK 
Mainland Europe 
North America 
a
occurence data taken from: UK-[20] Mainland Europe-[17] North America-[21-22], 
b
UK Chemicals 
Investigation Programme [19], 
c
[12]  
KEY: NSAID, non steroidal anti-inflammatory drug 
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2. Analytical strategies for fate evaluation 
Prior to laboratory work, the first step for drug determination in wastewaters is sampling. This 
process is fundamental to any strategy for monitoring, and careful consideration of sampling 
equipment, sample handling and types of samples is needed. It is beyond the scope of this 
review to examine further; however an excellent overview of sampling strategies has been 
given by Ort et al [28-29].  Nevertheless, it is important to highlight that to fully understand 
fate during wastewater treatment, determination in both aqueous and particulate phases of 
wastewaters is essential [9, 30]. 
 
Trace determination of drugs in aqueous wastewater fractions (typically 0.45 µm filtered) 
requires an enrichment step followed by chromatographic separation and mass spectrometry 
(MS) detection.  Sample pre-concentration and clean up commonly involves solid phase 
extraction (SPE), and can be undertaken off-line (using extraction systems not linked to 
analytical equipment) or on-line, where extraction and quantification are automated and 
linked together.  Off-line analysis tends to use up to 1 litre of sample, and Gros et al [31] 
investigated the efficacy of various SPE sorbents (Oasis HLB, Oasis MCX, Isolute C18 and 
Isolute ENV+) for the simultaneous extraction of 13 pharmaceutical drugs of varying 
physicochemical composition.  The Oasis HLB sorbent (polystyrene-devinylbenzene-N-
vinylpyrrolidone terpolymer) [32] (without pH adjustment) exhibited superior performance, 
utilising both hydrophilic and lipophilic retention mechanisms.  Consequently, a full suite of 
drugs (up to 90) can be extracted simultaneously off-line using this sorbent [17-18, 25, 33].  
The introduction of fully automated methods further reduces sample processing restrictions 
[34-35].  At present these are emerging techniques whose use are not widespread.  Their 
reproducibility and ability to use smaller total sample volumes mean they will supersede 
traditional labour intensive SPE protocols in commercial laboratories in the future.  Drug 
determination in the particulate phase of wastewaters is not routinely monitored but those 
methods which do, use ultrasonic solvent extraction (USE) [36] or most commonly, 
accelerated solvent extraction (ASE) [30, 37-40].  The application of pressure enables the use 
of extraction solvents (eg methanol) at temperatures much higher than their boiling point, 
increasing solubility and mass transfer [41].  Following extraction the solvent can be diluted 
in water to <5 % (v/v) and subjected to SPE as an aqueous fraction [38-39].  
 
Gas chromatography-mass spectrometry is well established for quantification of chemicals in 
environmental samples, achieving method quantitation limits (MQLs) ≤10 ng l-1 for some 
drugs [42-43].  However, derivatization of more polar drugs with toxic chemicals is required 
prior to analysis to improve volatility, thermal stability and sensitivity of detection, increasing 
cost and time of sample preparation.  A further disadvantage is the run time required for 
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analysis; often up to 1 hour per sample [42-43].  This has been a rate limiting step of such 
research in the past, severely restricting sample numbers which can be analysed.  Despite 
these limitations, methods report the ability to simultaneously measure ≥63 drugs of varying 
therapeutic class from a single injection by GC-MS following derivatization [44-45].  The use 
of LC coupled to tandem MS detection (MS/MS) improves sample throughput without the 
need for additional sample preparation [46].  Furthermore, the introduction of UPLC offers 
additional reductions in run times, whilst improving sensitivity over conventional LC [23].  
For UPLC, run times are generally less than 10 minutes with MQLs <100 ng l
-1
 for most 
drugs [17-18, 25].  However, a well known problem of environmental sample analysis by LC-
MS, with electrospray ionisation (ESI) source particularly, is the quenching influence 
(ionisation suppression) of sample matrix on analyte signal strength [23, 47].  The 
commercial availability of deuterated surrogates now offers substantial improvements in 
minimizing the impact of matrix interferences, improving accuracy of analysis and up to 50 
isotopic labelled standards are used in some multi-residue methods [35].    
 
The selection of MS/MS detector type is critical for analysis type (i.e., qualitative or 
quantitative). Quantitative analysis commonly employs a triple quadrupole (QqQ) due to its 
high sensitivity.  The use of hybrid detectors such as quadrupole time of flight (QqTOF) 
offers the ability to screen and identify unknown degradation products/metabolites.  Its full 
scan sensitivity, high selectivity and specificity enable structural elucidation of non-target 
species [32].  This is a significant advance in the determination of drug fate where 
degradation products in both biological and chemical processes are formed; enabling 
degradation pathways to be identified.  However, data processing can be time consuming due 
to the lack of searchable libraries, often requiring manual spectral interpretation [32, 46].  A 
further disadvantage of TOF detection is it generally offers lower sensitivity (3 to 5 times) 
than conventional MS/MS such as QqQ [48].  Thus, the ever increasing requirement to reduce 
MQLs for trace analysis confines its use to qualitative fate evaluation.  Alternatively, hybrid 
linear ion trap (LIT) Orbitrap instrumentation offers high sensitivity for environmental 
quantitation (as offered by QqQ) and the ability to perform accurate mass determinations for 
drug identification (as offered by TOF) [46].  Although Orbitrap technology has been used to 
screen environmental samples for unknowns [49], unequivocal confirmation of degradation 
products observed by non-target MS/MS screening requires a complementary analytical 
technique or use of analytical reference standards [50].  However, as degradation products are 
often not known, there is a subsequent lack of standards for these.  Further opportunities are 
offered by Fourier transform-MS which demonstrates unrivalled mass accuracy, rapid data 
collection, good dynamic range and, high sensitivity and resolution.  However, the high cost 
of such instrumentation limits its widespread application.   
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Overall, recent trends for drug determination in wastewaters tend to use a single stage Oasis 
HLB off-line SPE followed by UPLC with detection by QqQ [17, 25, 33] or LIT [18] (Table 
3).  These methods are well suited for the determination of multiple drugs in the aqueous 
phase of crude wastewaters and secondary effluents where their concentrations are relatively 
high.  However, monitoring EE2 at environmentally relevant levels requires devoted clean up 
protocols which can be laborious due to its inherently lower concentrations [23].  
Nevertheless, there is a lack of particulate phase analysis undertaken and the concentrations 
present in tertiary effluents continue to pose an analytical challenge.   
      
3. Drug removal by conventional wastewater treatment; the current problem 
Activated sludge is an extensively implemented secondary wastewater treatment process, 
effective for carbonaceous material removal and can be adapted for nutrient removal. 
Removals of many drugs (and other chemicals of anthropogenic origin) are also observed [6-
7].  Removal of drugs and other hazardous chemicals during treatment is attributed to 
biological degradation and sorption onto biomass [52-54].  Pharmaceutical drugs have low 
vapour pressures and pKa’s ranging from 3 to 10 (Table 1) restricting any removal by 
volatilization.  The relative resistance to biodegradation and/or sorption of some drugs makes 
enhancing removal by such processes difficult.  Ibuprofen, diclofenac and carbamazepine 
encompass extremities in susceptibility to biodegradation and sorption.  These represent drugs 
reasonably amenable to sorption and biodegradation (ibuprofen), sorption only (diclofenac) 
and neither sorption or biodegradation (carbamazepine), respectively.  Consequently, removal 
differs between one another during activated sludge treatment [6-7].  Solids retention time 
(SRT) (which is proportional to the food: micro-organism (F:M) ratio) is the simplest way of 
manipulating existing activated sludge operation in the short term and, is considered critical to 
the removal of non-drug derived hazardous chemicals [6-7, 27].  An increased SRT (>10 
days) is often cited as the condition required to achieve greatest hazardous chemical removal 
[6-7] but has little effect to removals of these drugs (Figure 1, Table 4).  Generally, diclofenac 
is removed by ≤50 % and any carbamazepine removal is negligible.  Negative drug removals 
are also observed during treatment and are considered attributable to the deconjugation of 
metabolites present in the crude stream [26].  Conjugates and intermediate chemicals tend to 
go undetermined by current analytical approaches.  Parent drugs are often above their 
legislative targets for consent in secondary effluents despite accounting for typical dilution 
ratios in the environment [19].  Source control would limit drug entry into wastewater, similar 
to what has been achieved with nonylphenol [23].  Without the availability of substitute 
drugs, less persistent and with a less burdensome environmental impact, this will not be 
achievable.  However, the possibility of separate treatment of urine
Table 3. Recently validated LC-MS/MS methods applied for the quantitation of drugs in environmental matrices 
No. of 
drugs 
Sample SPE Chromatography Detector 
Run 
time / 
min
-1
 
SE 
recovery 
/ % 
SE MQL 
/ ng l
-1
 
No. of drugs quantified in 
methods application Method 
benefits 
Method 
limitations 
Ref. 
Crude 
WW 
SE TE SW 
81 Aq. Oasis HLB UPLC QqLIT 
4
a
 
7
b
 
22-146 0.6-51 57
c
 59 28 45 √ XX  [18] 
47 Aq. Oasis HLB UPLC QqQ 10 49-127 0.8-170 - 37 - 31 √ X [25] 
74 Aq. Oasis HLB UPLC QqQ 
8
a
 
5
b
 
0-174 0.1-378 - - - 73 √ 
X 
 XX 
[17] 
90 Aq. Oasis HLB HPLC QqQ 25 5-246 0.1-78 - 63 - - √ X [33] 
33
d
 Aq. 
Oasis HLB 
+ 3 sorbents 
HPLC QqQ 36
e
 64-166 2.3-186 - - - 16 
√√ 
√√√ 
X [35] 
87 Aq. 
TurboFlow 
column 
HPLC QqQ 22
e
 12-345 0.1-164 - - - 44 
√ 
√√  
√√√ 
X 
XX 
[34] 
14 Part. Oasis HLB HPLC QqQ - 70-120 0.6-19
f,g
 - 11
g
 - - √√√√ X [40] 
60 Part. Oasis MCX UPLC QqQ 20 7-142
e
 0.1-20
f,g
 30
f
 - - - √ X [30] 
5 
Aq. 
Part. 
MIP HPLC QqQ 25 
95-105 
77-91 
4-12 
4-10
f,i
 
- 5
j
 - 4
f,i
 √√√√ 
X 
XXX 
[51] 
1
k
 
(EE2) 
Aq. 
Part. 
C18, NH
2 
Silica, NH
2
 
UPLC QqQ 9 
96
 
97 
0.06
 
2.96
f
 
1 1 - - 
√√√√ 
√√√√√ 
X 
XXXX 
[23] 
a
positive ionisation mode
 b
negative ionisation mode
 c
application is not a sequential train of processes 
 d
includes additional 55 chemicals in method
 e
includes on-line SPE time 
f
ng g
-1  g
de-watered sludge
 h
settled sewage
 i
sediment 
j
aqueous only 
k
includes 4 natural estrogens in method 
Key: MQL, method quantitation limit; SPE, solid phase extraction; SE, secondary effluent, WW, wastewater; TE, tertiary effluent; SW, surface water; Aq., aqueous; Part., 
particulate; QqLIT, linear ion trap; QqQ, triple quadrupole; MIP, molecularly imprinted polymer; √, high number of drugs varying in physio-chemical composition; √√, 
includes some known degradation products; √√√, fully automated, small sample requirements; √√√√, high recoveries for all drugs measured; √√√√√, very low MQL; X, 
application to real samples limited; XX, numerous drugs reported <MQL; XXX, limited to drugs of specific physio-chemical composition; XXXX, extensive sample pre-
treatment required 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Removals of ibuprofen (■, n=36), diclofenac (□, n=19) and carbamazepine (▲, n=25) by 
activated sludge operating at varying solids retention time.  Ibuprofen, diclofenac and 
carbamazepine represent drugs reasonably amenable to sorption and biodegradation, sorption 
only and neither sorption or biodegradation, respectively.  Inset, octanol-water coefficients, 
partition coefficients and degradation rate constants – a[16] b[53]   
(removal data obtained from: [6-7, 26, 55-62] – Table 4, no data reported as <MDL) 
 
 
streams may be an effective solution in some circumstances [63].  Additionally, membrane 
bioreactor systems generally achieve greater drug removals than conventional secondary 
processes [32, 60-61].  Without their application, the remaining alternative to enhance drug 
removal is the addition of a tertiary process or processes to an existing conventional 
secondary treatment asset (e.g., activated sludge).  This requires a process not excessively 
space consuming and can treat secondary effluents at relatively short contact times.  Some 
available options suiting these criteria include; biofiltration (sand or trickling filters), 
chemical (ozone) and adsorption (granular activated carbon) processes.  The fate and removal 
of drugs differ substantially between these systems.         
 
4. Drug fate and removal in tertiary processes  
4.1. Biologically active sand filters 
Drug removal by biofiltration processes (tertiary sand or trickling filters) is by physical and 
biological mechanisms.  Total removals by sand filters vary from 2 % for carbamazepine to 
>95 % for ibuprofen [64] (Figure 2, Table 5), similar to those achieved by activated sludge.  
Despite treating different wastewaters of differing composition, activated sludge and tertiary 
sand filters essentially rely on the same mechanisms.  Sand filters depend on a fixed biofilm 
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Table 4. Removal of ibuprofen, diclofenac and carbamazepine in activated sludge at varying SRT 
 
Drug 
Flow rate / 
m3 d-1 
SRT/ d-1 
HRT/ h-
1 
MLSS / 
mg l-1 
COD / 
mg l-1 
SS conc. 
/ ng l-1 
SE conc. 
/ ng l-1 
Removal 
/ % 
Ref. 
Ibuprofen - 0.3 - - - - - -1.0 [6] 
 - 1 - - - - - 9.0 [6] 
 626,000 1.9 7 - - 50,700 24,600 51.5 [55] 
 - 2 1.9 4,000 - 2,300 2,400 -4.2 [7] 
 47,860 2.2 13 - - 14,200 21,700 -52.8 [55] 
 185,000 2.7 12 - - 27,900 5,400 80.6 [55] 
 585,667 2.7 14 - - 58,200 6,200 89.3 [55] 
 3,967 3 10 3,030 113* - - 94.0 [26] 
 22,000 3 12 - 508.2 
13,355-
17,585 
1,420-
6,056 
82.5 [61] 
 645,000 3.8 8.6 - - 909 86.7 90.5 [58] 
 1,984 4.5 15 2,482 113* - - 94.0 [26] 
 409,000 4.6 8.0 - - 593 21.0 96.4 [58] 
 125,248 4.7 13 - - 21,800 300 98.6 [55] 
 1,199,000 5.0 7.1 - - 578 14.3 97.5 [58] 
 - 5.0 - - - - - 96.0 [6] 
 5,506 5.5 15 2,836 205* - - 95.0 [26] 
 15,300 5.5 15 1,743 154* - - 94.0 [26] 
 19,260 6 22 2,084 128* - - 98.0 [26] 
 125,000 7 12 2,000 - 1,966 40.0 98.0 [60] 
 20,000 6-10 35 - 510-680 5,700 88.5 98.4 [62] 
 210,000 8.4 8.9 - - 595 8.0 98.7 [58] 
 68,498 9.6 15 - - 27,300 2,700 90.1 [55] 
 - 9.6 - - - - - 92.0 [6] 
 17,994 10.5 13 2,105 51* - - 91.0 [26] 
 - 10-12 7.3 - - - - 91-99 [56] 
 366,898 12.6 23 - - 39,100 50.0 >99.9 [55] 
 60,000 12-14 22 
5,000-
6,000 
- 6,242 194 97.0 [57] 
 11,783 13 13.5 2,740 143-160 - - 86.0 [59] 
 - 17.0 - - - - - 99.0 [6] 
 - 22-24 16.8 - - - - 96-98 [56] 
 - 23.6 - - - - - 98.0 [6] 
 - 24.0 - - - - - 99.0 [6] 
 - 35.0 - - - - - 99.0 [6] 
 5,074 35.3 27 - - 58,900 50.0 >99.9 [55] 
 - 46 28.8 3,100 - 1,200 24.0 98.0 [7] 
 - 52 326 4,000 - 2,448 20.0 99.2 [7] 
Diclofenac - 1.0 - - - - - 0.0 [6] 
 - 2 1.9 4,000 - 1,400 1,300 7.1 [7] 
 3,967 3 10 3,030 113* - - 28.0 [26] 
 105,300 5 16 2,450 127* - - 22.0 [26] 
 - 5.0 - - - - - 36.0 [6] 
 5,506 5.5 15 2,836 205* - - -88.0 [26] 
 15,300 5.5 15 1,743 154* - - -103 [26] 
 19,260 6 22 2,084 128* - - 30.0 [26] 
 20,000 6-10 35 - 510-680 100 485 -79.4 [62] 
 - 9.6 - - - - - 9.0 [6] 
 17,994 10.5 13 2,105 51* - - -143.0 [26] 
 - 10-12 7.3 - - - - 22-33 [56] 
 - 17.0 - - - - - 13.0 [6] 
 - 22-24 16.8 - - - - 30-34 [56] 
 - 23.6 - - - - - 13.0 [6] 
 - 24.0 - - - - - 52.0 [6] 
 4,554 30 23 4,554 178* - - 77.0 [26] 
 - 35.0 - - - - - 3.0 [6] 
 - 46 28.8 3,100 - 905 780 13.8 [7] 
 - 52 326 4,000 - 3,190 1,680 47.3 [7] 
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Table 4 (continued) 
Drug 
Flow rate / 
m3 d-1 
SRT/ d-1 
HRT/ h-
1 
MLSS / 
mg l-1 
COD / 
mg l-1 
SS conc. 
/ ng l-1 
SE conc. 
/ ng l-1 
Removal 
/ % 
Ref. 
Carbamazepine - 0.3 - - - - - 0.0 [6] 
 17,364 0.9 12 - - 1,300 800 38.5 [55] 
 - 1.0 - - - - - -9.0 [6] 
 626,000 1.9 7 - - 800 700 12.5 [55] 
 - 2 1.9 4,000 - 670 690 -3.0 [7] 
 47,860 2.2 13 - - 1,100 2,300 -109.1 [55] 
 185,000 2.7 12 - - 1,200 1,700 -41.7 [55] 
 585,667 2.7 14 - - 600 800 -33.3 [55] 
 645,000 3.8 8.6 - - 55.9 32.1 42.6 [58] 
 6,243 4.1 14 - - 1,000 500 50.0 [55] 
 409,000 4.6 8.0 - - 43.1 46.9 -8.6 [58] 
 125,248 4.7 13 - - 700 800 -14.3 [55] 
 1,199,000 5.0 7.1 - - 50.5 45.4 10.2 [58] 
 - 5.0 - - - - - 6.0 [6] 
 210,000 8.4 8.9 - - 173 117 32.4 [58] 
 68,498 9.6 15 - - 700 700 0.0 [55] 
 - 9.6 - - - - - 9.0 [6] 
 - 10-12 7.3 - - - - 0-18 [56] 
 366,898 12.6 23 - - 900 1,700 -88.9 [55] 
 - 17.0 - - - - - -11.0 [6] 
 - 22-24 16.8 - - - - 0-5 [56] 
 - 35.0 - - - - - 1.0 [6] 
 5,074 35.3 27 - - 1,000 900 10.0 [55] 
 - 46 28.8 3,100 - 325 426 -31.1 [7] 
 - 52 326 4,000 - 704 952 -26.1 [7] 
SRT, solids retention time; HRT, hydraulic retention time; MLSS, mixed liquor suspended solids; 
COD, chemical oxygen demand; SS, settled sewage; SE, secondary effluent 
*Biological oxygen demand 
 
 
 
 
 
 
Figure 2. Removals of ibuprofen, diclofenac and carbamazepine reported in the literature for 
biofiltration, chemical and adsorption processes.  Ibuprofen, diclofenac and carbamazepine 
represent drugs reasonably amenable to sorption and biodegradation, sorption only and neither 
sorption or biodegradation, respectively (removal data obtained from: [64-75] - Table 5, 6 and 7) 
a
1/3 removed <MQL 
b
2/3 removed <MQL 
c
3/4 removed <MQL 
d
4/5 removed <MQL 
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Table 5. Removal of drugs from environmental waters by biofiltration processes 
Drug Proce
ss 
Temp.°
C 
HRT 
h-1 
Wastewate
r type 
Upfront 
process 
SE. 
conc. / 
ng l-1 
TE 
conc. / 
ng l-1 
Removal 
/ % 
Ref. 
Ibuprofen SF - 4-6 Municipal - 11,700a 1,170 90 [67] 
 SF - 0.3 River - 276 <14 >95 [64] 
 SF - 1 Municipal ASP - - 73b [68] 
Diclofenac SF - 4-6 Municipal - 820a 197 76 [67] 
 SF - 0.3 River - 252 181 28 [64] 
 SF 22 2 Municipal - - - 23 [73] 
Carbamazepin
e 
SF - 4-6 Municipal - 2,060a 1,833 11 [67] 
 SF - 0.3 River - 85 84 2 [64] 
 SF - 1 Municipal ASP - - 22b [68] 
Naproxen SF - 4-6 Municipal - 1,570a 314 80 [67] 
 SF - 0.3 River - 170 24 86 [64] 
 SF - 1 Municipal ASP - - 32b [68] 
Ketoprofen SF - 1 Municipal ASP - - 16b [68] 
EE2 SF - 0.3 River - 316 246 22 [64] 
 SF 18 - Municipal ASP - 0.2 82 [76] 
 SF - - Municipal ASP - - 7 [77] 
 SF - - Municipal OD - - 9 [77] 
 SF 22-25 - Municipal - 109 64 41 [78] 
Erythromycin SF - 0.3 River - 104 75 28 [64] 
 SF 19-22 0.4 Municipal ASP - - 20 [79] 
 
 
comprised of a diverse community of micro-organisms embedded within a matrix of 
extracellular polymeric substances (EPS) consisting of proteins, nucleic acids, 
polysaccharides and amphiphilic polymeric compounds [81].  The composition of EPS shifts 
with biofilm age [81], and is known to influence EE2 uptake [54].  The high tendency of 
some drugs to partition to solid organic matter, similar to biofilms has been confirmed by 
ASE followed by LC-MS/MS analysis [30, 38-40].  Those hydrophobic drugs with a 
comparatively high log Kow (>4) (e.g., diclofenac and fluoxetine) are considered to have a 
tendancy to sorb to solid organic surfaces such as biofilms [82-83].  However, sorption cannot 
be predicted by hydrophobicity alone [83-84]; other properties such as molecular weight and 
ionic speciation are of known importance [83], as is the nature of other dissolved species with 
which they may interact [85].  Extracellular polymeric substances offer both anionic and 
cationic functional groups for the exchange of charged species [83].  At a pH typical of 
municipal wastewaters (e.g., 7-8), EPS is negatively charged [83] with pKa’s generally 
ranging from 6.2 to 10.1 [86].  Those drugs whose pKa is <7 (e.g., ibuprofen, diclofenac,  
 
 13 
 
 
 
 
 
Figure 3.  Biological degradation products (DP) of diclofenac (A, adapted from [90]) and the 
proposed biotransformation pathway of bezafibrate (B, adapted from [50])  
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naproxen, ketoprofen and oxytetracyline) (Table 1) will themselves be negatively charged and 
repulsion with the biofilm may restrict sorption.  Removal will also be influenced by biofilm 
porosity.  Drugs whose molecular size is comparatively large (e.g., erythromycin), will have a 
reduced rate of mass transfer between the liquid medium and the biofilm, limiting partitioning 
[83].  Drugs which are comparatively smaller (<300 g mol
-1
) and relatively hydrophobic in 
nature (log Kow’s >3) (e.g., ibuprofen, diclofenac, naproxen, ketoprofen, propranolol and EE2, 
Table 1) are expected to partition well within the biofilm matrix.   
 
Sorption is also considered to be an intermediate step in biodegradation [52, 54].  Assuming 
similar behaviour to EE2 and other hazardous chemicals in biological processes, drug 
biodegradation is likely to be mediated on the surface and/or within intact bacterial cells [52, 
54, 87].  Free ammonia mono-oxygenase enzymes released by lysis extracellularly are not 
likely to be involved in biodegradation [52, 87]. Gaulke et al [88] observed that EE2 removal 
in nitrifying batch studies was not by nitrifying bacteria activity, dismissing the hypothesis 
that nitrification augments EE2 removals [89].  The synthesis of nitro-EE2 confirmed that 
EE2 is nitrated at high ammonia feed concentrations caused by the high production of 
nitrates; EE2 removal here is an artefact of laboratory scale investigation.  Biodegradation at 
environmentally representative conditions is by heterotrophic micro-organisms, capable of 
scavenging a broad range of organic material [87].  Interestingly, differences in 
biodegradation are observed for drugs which sorb similarly to biomass (e.g., ibuprofen and 
diclofenac, Figure 1) suggesting chemical structure controls susceptibility to biological attack.  
The structure of ibuprofen is comparatively simpler than that of diclofenac (i.e., single 
aromatic ring and non-halogenated, Table 2) which may aid its biodegradation.  Drugs of 
increasing structural complexity and elemental diversity such as antibiotics (e.g., ofloxacin, 
erythromycin and oxytetracycline) may be less favourable to biodegradation especially 
considering their possible toxicity to bacteria.  However, ‘biodegradation’ here is not 
indicative of complete mineralisation. Drugs rich in functional groups provide more possible 
sites for biological attack, inducing a change to the parent structure.  Kosjek et al [90] 
investigated the degradation products of diclofenac, utilising Oasis HLB SPE and UPLC 
separations to ensure adequate sensitivity required by QqTOF.  In full scan mode the total ion 
chromatogram (TIC) was screened and a protonated compound was then selected for further 
product ion scans [90].  Accurate mass measurements and in-source fragmentation enabled 
chemical structure elucidation of three biotransformation products (Figure 3A).  Similarly 
Helbing et al [50] used LIT-Orbitrap MS to identify five degradation products of bezafibrate 
(Figure 3B).  The dehydrogenation product (DP1) is structurally similar to the parent drug 
indicating it may behave similarly in the environment. 
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4.2. Chemical oxidation  
Titanium dioxide photocatalysis [91] and Fenton chemistry (i.e., catalytic oxidation of 
hydrogen peroxide) [92] have been applied to water treatment however ozone is the most well 
established and studied of the chemical processes for drug removal.  Ozone treatment 
enhances the removal of all drugs including carbamazepine where removals of ≥96 % are 
observed [65, 70-71, 73-74] (Figure 2, Table 6).  However, typical ozone doses applied 
during water treatment often do not enable full mineralization of drugs [93], likely to be 
caused by the clouding influence of the matrix.  Wastewaters contain relatively high 
concentrations of bulk organics which can shield targeted chemicals from removal, quenching 
the ozone dose.  Furthermore, Huber et al [93] observed that following removal of EE2 from 
clean water by a high ozone dose, a slow re-appearance of the drug (0.1-0.5 % of the initial 
concentration) occurred.  It is hypothesized that some EE2 is in the form of hydroperoxides 
which are not readily reactive to ozone.  This could be greater in wastewater where clouding 
will reduce reaction kinetics and this will hinder the complete mineralisation of the parent 
drug.  Degradation by ozonation can occur selectively by direct ozone attack itself and non-
selectively by hydroxyl radicals formed upon ozone decay [93].  Ozone reacts rapidly with 
phenols at neutral or basic pH [94] therefore it will readily attack the phenolate anion of EE2 
and oxytetracycline.  It also selectively attacks amines and double bonds of aliphatic 
chemicals [95].  The chemical structure of all the drugs considered here (except ibuprofen) 
are highly susceptible to direct ozone attack (Table 2).  Hydroxyl radicals are less selective 
and react with a range of chemical functional groups.  The non-selective behaviour of the 
hydroxyl radicals can induce complex reaction pathways [93].  Numerous authors observed 
high removals of various drugs by ozone treatment, often to concentrations below their MQLs 
[65, 70-71].  However, complete removal of the parent drug does not necessarily represent 
removal of toxicity.  Structurally similar degradation products of potential toxicity can be 
formed and remain undetected using conventional MS/MS (i.e., QqQ).  A large number of 
degradation products for various drugs have been observed [93, 96].  Non-target screening of 
ozone treated water enabled determination of 17 degradation products of diclofenac [96] 
(Figure 4).  The majority of these products are structurally similar to the parent drug 
indicating similar behaviour in the receiving environment.  Again these were identified by 
Oasis HLB extraction and QqTOF detection.  Accurate mass spectra were collected at mass to 
charge (m/z) ratios >50 encompassing all degradation products of notable size.     
 
4.3. Adsorption by activated carbon 
Activated carbon often contained in a packed bed or filter is a highly porous medium offering 
a large internal surface area for sorption to take place.  Performance is dependant on activated 
carbon properties (e.g., pore size, surface charge) and solute characteristics (e.g., shape, size) 
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Table 6. Removal of drugs from environmental waters by ozone treatment 
Drug Process 
Chemical 
dose 
HRT 
h-1 
Wastewater 
type 
Upfront 
process 
SE. 
conc. / 
ng l-1 
TE 
conc. / 
ng l-1 
Remova
l / % 
Ref. 
Ibuprofen Ozone 
10-15 mg 
l-1 
0.3 Municipal ASP 130 <50 >62 [65] 
 Ozone 2 mg l-1 0.2 
Surface 
waters 
- - - 40-77 [75] 
 Ozone 3 mg l-1 0.5 Municipal 
ASP + 
SF 
- - >46a [68] 
Diclofenac Ozone 
0.6 g O3 g 
DOC0
−1 
- Municipal ASP 2,000 <10 >99 [71] 
 Ozone 3 mg l-1 0.3 Municipal - - - 92 [73] 
 Ozone 50 µM <0.1 Municipal - 433 <1 >99 [70] 
 Ozone 
10-15 mg 
l-1 
0.3 Municipal ASP 1,300 <50 >96 [65] 
Carbamazep
ine 
Ozone 
0.6 g O3 g 
DOC0
−1 
- Municipal ASP 900 <1 >99 [71] 
 Ozone 3 mg l-1 0.3 Municipal - - - 96 [73] 
 Ozone 130 µM 0.1 Municipal - 106 <1 >99 [70] 
 Ozone 1 mg l-1 - Municipal GAC 67 1 99 [74] 
 Ozone 
10-15 mg 
l-1 
0.3 Municipal ASP 2,100 <50 >98 [65] 
Naproxen Ozone 3 mg l-1 0.5 Municipal 
ASP + 
SF 
- - >99a [68] 
 Ozone 
10-15 mg 
l-1 
0.3 Municipal ASP 100 <50 >50 [65] 
Bezafibrate Ozone 
0.6 g O3 g 
DOC0
−1 
- Municipal ASP 1,500 345 77 [71] 
 Ozone 340 µM 0.3 Municipal - 115 4 97 [70] 
 Ozone 2 mg l-1 0.2 
Surface 
waters 
- - - >98 [75] 
Fluoxetine Ozone 50 µM <0.1 Municipal - 17 <2 >88 [70] 
Ketoprofen Ozone 3 mg l-1 0.5 Municipal 
ASP + 
SF 
- - 73a [68] 
 
[69].  Preferential attraction to the activated carbon surface is by hydrogen bonding and 
London forces creating a strong binding affinity.  Even moderately hydrophobic chemicals 
(log Kow >2) have a high propensity to removal [95].  The availability of some drugs as anions 
causes them to be attracted to the carbon surface.  As a result substantial removals of 
hydrophobic and hydrophilic drugs have been observed by granular activated carbon (GAC) 
[66, 73-74] (Figure 2, Table 7).  Carbamazepine removals up to 97 % have been achieved 
[73].  Despite the very hydrophilic nature of oxytetracycline (Table 1), its large molecular size 
is likely to be entrapped within the highly porous structure of the activated carbon.  At full-
scale treatment processes low removals have been observed for some drugs; ibuprofen (16 %) 
[69], carbamazepine (16-23 %) [69, 72] and propranolol (17 %) [72] (Table 7).  The quality 
of the secondary effluent will have a significant influence on the performance of GAC 
through the competition for available sorption sites [69].  The frequency of 
replacement/regeneration of the activated carbon medium is another controlling factor to its 
success, especially whilst treating wastewaters comprising relatively high concentrations of 
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bulk organics.  This may account for large variations in drug removals observed between 
processes.  Chiu et al [97] demonstrated the possibility of in situ catalytic regeneration of 
GAC using iron nano-catalysts.  This could provide an effective means of regeneration in the 
future, limiting variations in performance currently observed.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Degradation intermediates formed by ozone treatment of diclofenac and proposed 
degradation pathways (adapted from [96]) 
 
 
 
5. Future trends 
Secondary effluents typically demand analytical MQLs in the low ng l
-1
 range to determine 
most drugs.  Reported analytical methods are well suited for determining drugs in the aqueous 
phase of secondary effluents.  To demonstrate, no data in Figure 1 (and Table 4) was reported 
below MQL (n=80).  Despite proposed legislative targets being applied to the aqueous phase  
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Table 7. Removal of drugs from environmental waters by adsorption processes 
Drug Process 
HRT 
h-1 
Wastewater 
type 
Upfront 
process 
SE. 
conc. / 
ng l-1 
TE 
conc. / 
ng l-1 
Removal 
/ % 
Ref. 
Ibuprofen GAC 0.3 Municipal ASP 64 <10 >84 [74] 
 GAC - Raw water - 23 <1 >96 [66] 
 GAC - Surface water - 1.1 <1 >10 [69] 
 GAC - - SF 8,760 7,325 16 [69] 
Diclofenac GAC 0.3 Municipal ASP 99 <10 >90 [74] 
 GAC - Municipal ASP - - >98 [72] 
 BAC 2 Municipal MBR - - 92 [73] 
 GAC - - SF 3.2 <1 >69 [69] 
Carbamazepine GAC 0.3 Municipal ASP 250 67 73 [74] 
 GAC - Municipal ASP - - 23 [72] 
 BAC 2 Municipal MBR - - 97 [73] 
 GAC - Raw water - 8 <1 >87 [66] 
 GAC - Surface water - 2.2 <1 >55 [69] 
 GAC - - SF 199 168 16 [69] 
Propranolol GAC - Municipal ASP - - 17 [72] 
EE2 GAC - Municipal ASP - - >43 [72] 
Erythromycin GAC 0.3 Municipal ASP 270 28 90 [74] 
 BAC 2 Municipal MBR - - 92 [73] 
HRT, hydraulic retention time; SE, secondary effluent; TE, tertiary effluent; ASP, activated sludge 
plant; GAC, granular activated carbon; BAC, biologically activated carbon; MBR, membrane 
bioreactor 
 
 
of wastewaters (i.e., a pre-filtered sample); suspended solids can provide a pathway to their 
release into the environment [30].  Their determination in the particulate phase is also 
essential for fate evaluation.  Suspended solids are ubiquitous to wastewaters and can vary 
spatially and temporally.  Particulate bound drugs often go undetermined (Table 3), owing to 
the complexity of the matrix and the additional analytical requirements it demands.  The 
proposed requirement to undertake particulate phase analysis to determine drug fate is most 
pertinent to secondary processes which receive relatively high concentrations of suspended 
solids.  The relatively hydrophobic nature of some drugs can cause them to partition well to 
solids.  For example crude wastewaters can contain >50 % of fluoxetine bound to particulates 
[30].  Monitoring here enables complete process mass balances to be determined, aiding fate 
and performance understanding.  Particulate fate understanding may indicate a clouding 
influence during treatment which limits removal.  Activated sludge sorption and 
biodegradation may be restricted for drugs associated with particulates in the receiving 
wastewater.  This could lead to conventional process optimisation to enhance drug removal.  
For example, the use of micro-screens in place of conventional primary sedimentation tanks 
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could enhance particulates removal from the crude stream.  However, there is a substantial 
gap between drug concentrations achieved by the current operations of existing secondary 
assets and proposed legislative targets [19] (Table 2, Table 4).  Therefore there is an expectant 
need for tertiary treatment technologies to target these specific chemicals.    
 
Tertiary treatment processes enhance drug removal, significantly reducing effluent 
concentrations.  To fully ascertain tertiary process performance, analytical methods require 
MQLs <10 ng l
-1 
[64, 70-71, 74], and ideally <1 ng l
-1
 [66, 69-71] (Tables A2-4).  This poses a 
further analytical challenge as such concentrations cannot be ascertained for the majority of 
drugs with current MQLs.  To illustrate, concentrations of the representative drugs; ibuprofen, 
diclofenac and carbamazepine in sand filtration, ozone and activated carbon treated effluents 
were reported below MQL in 49 % of cases (n=35) (Figure 2).  Despite these being below 
proposed legislative targets for most drugs (Table 2), monitoring at these concentrations is 
needed as the cumulative toxicological effect of drugs is not known.  This could result in a 
future reduction in legislative requirements.  To illustrate, the previous EE2 predicted no 
effect concentration (PNEC) in the UK was 0.1 ng l
-1
 [98].  The proposed EQS is now 0.035 
ng l
-1
 following its classification as a priority hazardous chemical [12].  This has created a 
serious analytical burden as such concentrations are now beyond current analytical 
capabilities [23].  Lowering current MQLs is also needed to assess breakdown reaction 
completeness.  The first stage of this is to determine parent drug removal.  Further 
investigation of specific breakdown mechanisms to understand the criticality between parent 
drug final concentration, and degradation product production is needed.  Methodologies to 
quantify the full range degradation products will be restricted in the short term by the lack of 
unique reference standards available for these.  However, the identification of numerous 
degradation products in both biological and chemical processes has brought attention to their 
presence and created a demand for their commercial availability (Figures 3-4).  The 
complimentary use of biological assays would improve understanding of the synergistic 
toxicological effect of multiple drugs and their degradation products at low concentration.  
Process design and operation must integrate the removal of these intermediates which can be 
of greater concern than the parent chemical due to their subsequent transformation to more 
toxic chemicals in the environment [47].     
 
Lowering drug MQLs requires existing analytical method optimisation.  The low recoveries 
(<50 %) typically stipulated prior to internal standard correction [25], can be improved to 
reduce the achievable MQL.  Baker and Kasprzyk-Hodern [99] gave an excellent account of 
sample preparations parameters which can influence recovery.  For example drugs can be 
adsorbed onto glassware surfaces during handling and processing.  Using silanized SPE 
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extract vials gave recoveries six times higher than non-silanized vials for some drugs.  All 
glassware used during sample collection and processing requires silanization to ensure 
maximum recoveries.  Silanization of glassware is not mentioned in the procedures of most 
reported analytical methods [17-18, 25, 33].  Improving chromatographic separations could 
also significantly increase detection capabilities. Incorporating a large number of drugs into a 
single short UPLC run (<10 minutes) results in a number of co-eluting peaks [17-18, 25].  
Despite the use of mass scanning windows which typically range from 0.3 to 2 minutes in 
length for UPLC separations [17-18], sensitivity can be lost whilst simultaneously scanning 
for a number of transitions registered at the same time [17].  To demonstrate, Gros et al [18] 
reports up to 10 drugs co-eluting within a 0.1 minute time period with scanning windows of 
0.5 minutes.  Thus, only monitoring for one drug (of most criticality) in this time period could 
increase sensitivity and notably reduce the MQL.   
 
Tertiary processes receive secondary effluents comprising comparatively high concentrations 
of dissolved organics (e.g., colloids).  However, knowledge of drug behaviour in the charged 
colloidal fraction of wastewater is limited.  Shen et al [100] successfully showed humic acid, 
a small molecular weight charged species could effectively retain the hormone, estrone in 
solution.  This can restrict sorption in tertiary processes characterised by very short contact 
times.  Furthermore, the complexity of the colloidal fraction and its interaction with the drugs 
could also lead to incomplete breakdown reactions in both biological and chemical processes.  
A fractionation step during sample pre-treatment to separate dissolved colloids by molecular 
weight will aid this.  It is postulated that drugs will preferentially be in specific size fractions.  
This is likely to vary between drugs due to the range of physicochemical behaviour they 
exhibit.  Understanding drug fate in the colloidal fraction of wastewater is essential for 
tertiary process selection, diagnosis and optimisation.      
 
6. Conclusion 
Advances in both quantitative and qualitative determinations of pharmaceutical drugs have 
aided the understanding of their occurrence and fate during wastewater treatment.  A robust 
understanding of tertiary process performance is now needed by improving analytical focus.  
An appropriate treatment strategy could then be implemented to ensure adequate protection of 
the aquatic environment is achieved.  
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